Piper Jaffray Sees Increased Chance of Trius (TSRX) Partnering in Europe Following Tedizolid Data
Tweet
Share
E-mailGet Alerts TSRX Hot Sheet
Price: $13.63 --0%
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Shares of Trius Therapeutics (Nasdaq: TSRX) have been very volatile Monday as the price vacillates around the 200-day SMA. Following a gap higher at the open, shares turned negative after a test of this technical level, however shares are once again higher and above the moving average.
Investors in the stock may be considering an earlier research note from Piper Jaffray's Edward Tenthoff. The analyst suggested recent data on tedizolid could strengthen Trius' chances of partnering with a European company. The analyst maintains an Overweight rating and a $13 price target on shares of Trius.
Investors in the stock may be considering an earlier research note from Piper Jaffray's Edward Tenthoff. The analyst suggested recent data on tedizolid could strengthen Trius' chances of partnering with a European company. The analyst maintains an Overweight rating and a $13 price target on shares of Trius.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
- Deere (DE) PT Lowered to $728 at UBS as Agricultural Machinery Cycle Gets Closer
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
